Stocks · Health care · Pharmaceutical Preparations

Avalo Therapeutics, Inc.

AVTX Clue Score19
United States Fiscal year ends December CIK 0001534120 Results filed 5 Nov 2026

What the insiders did Mostly scheduled

By person

11 insiders · 43 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Christopher Ryan Sullivan
Chief Financial Officer
—
$3.72M (17) scheduled
−$3.72M
39,900
$651.71K
+3,322%
Mittie Doyle
Chief Medical Officer
—
$2.98M (17) scheduled
−$2.98M
51,776
$845.68K
+399.1%
Paul Varki
Chief Legal Officer
—
$1.51M (5) scheduled
−$1.51M
32,576
$532.08K
+214.0%
Jonathan Goldman
Director
—
$162.94K (2) scheduled
−$162.94K
3,166
$51.71K
—
Mitchell Chan
Director
—
$72.46K (1) scheduled
−$72.46K
3,166
$51.71K
—
Jennifer Riley
Chief Strategy Officer
—
$52.01K (1)
−$52.01K
37,041
$605.01K
+451.1%
Garry Arthur Neil
Chief Executive Officer
—
—
—
190,314
$3.11M
+317,090%
Gilla Kaplan
Director
—
—
—
6,333
$103.44K
—
Samantha Truex
Director
—
—
—
6,333
$103.44K
—
Aaron Kantoff
Director
—
—
—
6,333
$103.44K
—
June Sherie Almenoff
Director
—
—
—
4,167
$68.06K
—

No percentages here. This company's share count has moved by a factor of 5.0 over the window, from 10,671,934 to 53,629,989 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.